close

News Center

Latest News

Prevention & Control, Research

Living in disadvantaged neighborhoods may contribute to stress and aggressive prostate cancer in African American men

Jul 25, 2024

image_of_baltimore People living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, according to new research published in JAMA Network Open, which could contribute to higher rates of aggressive prostate cancer in African American men.

Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, according to new research published in JAMA Network Open, which could contribute to higher rates of aggressive prostate cancer in African American men. The study was co-led by VCU Massey Comprehensive Cancer Center and the University of Maryland School of Medicine (UMSOM).

African American men have a higher incidence of prostate cancer and are more than twice as likely to die from the disease than White men in the U.S. They are often diagnosed with an aggressive cancer and at an earlier age, but the reasons are not well understood.

“Our findings suggest an impact of living in disadvantaged neighborhoods – which more commonly affects African Americans – on stress-related genetic pathways in the body. We believe this may increase an individual’s risk of aggressive prostate cancer and contribute to prostate cancer disparities by race,” said senior author Kathryn Hughes Barry, Ph.D., M.P.H., assistant professor in the Department of Epidemiology and Public Health at UMSOM and a cancer epidemiology researcher at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).

The study found that neighborhood disadvantage was associated with significantly higher activity, or expression, of stress-related genes. Experiencing extreme hardships or trauma can affect how much the genes in our DNA are expressed, setting off a cascade of events that can give rise to cancer or other negative health consequences.

“The findings from our study support and build on existing research on the emerging importance of neighborhood factors and chronic stress to better understand aggressive prostate cancer and persistent racial disparities,” said the study’s first author Joseph Boyle, Ph.D., who is a T32 postdoctoral research fellow and biostatistician at Massey.

David C. Wheeler, Ph.D., M.S., M.P.H., late member of the Cancer Prevention and Control research program at Massey and a professor in the Department of Biostatistics at the VCU School of Population Health, was co-senior author of this study.

Five genes that had higher expression in this study are related to inflammation, which is relevant to prostate cancer, among other health conditions. Increased inflammation has been linked with a greater chance of developing prostate cancer or a greater likelihood that the cancer will progress in men who have the disease. The gene with the strongest link was HTR6, part of the serotonin pathway, which helps carry messages between the brain and other parts of the body. HTR6 also contributes to other pathways that are thought to help regulate the body’s immune response, and various HTR genes have been linked with lethal prostate cancer.

Barry said this observational study, which analyzed 105 stress-related genes from more than 200 African American and white men with prostate cancer, is among the first to suggest a possible link between neighborhood socioeconomic factors and RNA expression in prostate tumors. RNA (ribonucleic acid) comes from DNA and is involved in producing proteins that help the cell function.

“We need to conduct larger studies to investigate the interrelationships of different neighborhood factors, individual-level factors, tumor biology, tumor aggressiveness and patient outcomes to help inform interventions to reduce prostate cancer disparities,” Barry said. She and her colleagues plan a broader follow-up study that would include data from patients in other regions of the U.S.

The research team analyzed tumor tissue from 218 men with prostate cancer who underwent radical prostatectomy surgery to remove their prostate at the University of Maryland Medical Center (UMMC) from 1992-2021. Of these, 168, or 77%, reported their race as African American and the remaining 50 patients reported their race as white.

Researchers evaluated neighborhoods where patients lived at the time of their diagnosis, relying on two indexes that measured neighborhood deprivation, taking into account income, education, employment and housing quality. They also looked at racial segregation and historical redlining in which certain neighborhoods were systematically denied mortgage applications or refinancing, often based on race. While historical redlining occurred in the 1930s, such racist housing policies have led to long-term disinvestment and disadvantage that have been linked with worse health outcomes — including cancer outcomes — in the present day. Supporting the long-term impact of such policies, the current study observed that neighborhoods in the Baltimore area that were formerly redlined also tended to have higher disadvantage today.

Consistent with previous research, the current study also found that African American participants were more likely to live in disadvantaged neighborhoods than their white counterparts. Higher degrees of disadvantage occurred in Baltimore City compared with the rest of Maryland. Within Baltimore, higher disadvantage occurred in the central and western areas of the city.

The research was funded by an American Cancer Society Institutional Research Grant and several grants from the National Cancer Institute (NCI). The Maryland Department of Health’s Cigarette Fund Restitution Program and the National Center for Advancing Translational Sciences provided additional financial support.

This article was repurposed from an original article published by the University of Maryland Medical System.

Written by: Karen Warmkessel

Related News


Research, Clinical, Technology

VCU team has designs on a game-changer in women’s cancer treatment


Get access to new, innovative care

Get access to new, innovative care

Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.

Search clinical trials
Find a provider

Find a provider

Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.

Find a provider